The Science of Peptide Bioavailability: Oral vs Injectable vs Nasal

Written by NorthPeptide Research Team  |  April 16, 2026

For laboratory and research use only. Not for human consumption.

Every time a researcher reconstitutes a peptide and prepares a dose, they’re working around one of biology’s most effective defense systems: the gastrointestinal tract. The gut evolved to break down proteins and peptides into amino acids. From the stomach’s acidic hydrolysis to the pancreatic proteases of the small intestine to the brush border enzymes of the intestinal epithelium — the GI tract is extraordinarily efficient at dismantling exactly the molecules that peptide researchers want to keep intact.

Bioavailability is the percentage of an administered dose that reaches systemic circulation in active form. For most peptides administered orally, that number approaches zero. For subcutaneous injection, it typically exceeds 75%. Understanding why these routes differ — and what researchers have done to overcome the barriers — is foundational for anyone working in peptide science.

Why Oral Peptide Delivery Is So Difficult

The obstacles to oral bioavailability for peptides are not a single problem — they’re four overlapping problems operating simultaneously.

1. Gastric Acid Hydrolysis

The stomach maintains a pH of approximately 1.5–2.0. At this acidity, peptide bonds — the amide linkages that hold amino acids together — undergo acid hydrolysis. Longer peptides with more bonds are more vulnerable. Many research peptides begin breaking down within minutes of entering the gastric environment. BPC-157 is a notable exception, demonstrating unusual acid stability in preclinical models, but it is an outlier rather than the rule (PMC11859134).

2. Enzymatic Degradation

Even peptides that survive gastric acid encounter a second wave of proteolytic enzymes in the small intestine. Pancreatic proteases (trypsin, chymotrypsin, elastase, carboxypeptidases) are secreted from the pancreatic duct and systematically cleave peptide bonds with remarkable specificity. The intestinal brush border adds additional peptidases — including dipeptidyl peptidase-4 (DPP-4), which is specifically relevant to incretin-based peptides like GLP-1. Native GLP-1 has a plasma half-life of approximately 1–2 minutes primarily due to DPP-4 cleavage. Injectable GLP-1 analogs like semaglutide require specific Aib2 substitutions to resist DPP-4 degradation — and they’re still administered by injection or as a specially engineered oral formulation (PMC7499355).

3. Intestinal Epithelial Barrier

Even if a peptide survives enzymatic attack, it must cross the intestinal epithelium to enter the portal circulation. The GI lining is designed to absorb small molecules through transcellular transport but is largely impermeable to peptides above approximately 500 Da. Most research peptides are 1,000–5,000+ Da. Larger peptides cannot passively diffuse across epithelial cells and have no specific transporters that would actively carry them across.

4. Hepatic First-Pass Metabolism

Any peptide absorbed from the small intestine enters the portal vein and passes through the liver before reaching systemic circulation. Hepatic peptidases and metabolic enzymes can further reduce the fraction of intact peptide that ultimately reaches target tissues. This first-pass effect is particularly significant for larger peptides and adds another layer of loss on top of GI degradation.

The combined effect of these four barriers is why, for most peptides, oral bioavailability is essentially unmeasurable. The molecule simply does not survive the journey.

Subcutaneous Injection: The Research Standard

Subcutaneous injection — delivery into the tissue between the skin and the muscle — bypasses all four barriers described above. Injected peptides are absorbed from the subcutaneous depot directly into local capillaries and the lymphatic system, eventually reaching systemic circulation without encountering gastric acid, pancreatic enzymes, the intestinal epithelium, or hepatic first-pass metabolism.

Bioavailability via the subcutaneous route for well-designed research peptides typically ranges from 75% to over 90%, depending on the specific compound, injection site, and formulation. This compares to near-zero for most oral peptide administrations.

The subcutaneous route also allows precise control over the delivery rate. Long-acting peptides like semaglutide, retatrutide, and survodutide achieve their extended half-lives partly through albumin-binding modifications that create a slow-release depot effect at the injection site — the subcutaneous fat acts as a reservoir from which peptide slowly enters circulation (PMC12026077).

Intravenous and Intramuscular Routes

Intravenous (IV) injection achieves 100% bioavailability by definition — the peptide enters circulation directly — but is rarely used in routine peptide research due to practical constraints and the need for sterile technique. Intramuscular (IM) injection falls between subcutaneous and IV in absorption rate, with bioavailability comparable to subcutaneous for most peptides but with faster absorption due to higher vascularity in muscle tissue.

The SNAC Solution: How Oral Semaglutide Works

The development of Rybelsus — oral semaglutide — is one of the most important recent advances in peptide delivery science. Novo Nordisk achieved oral bioavailability for a GLP-1 receptor agonist not by modifying the peptide’s structure for gut stability, but by co-formulating it with a small molecule called SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate).

SNAC works through a local absorption-enhancing mechanism rather than a systemic permeability enhancer. When oral semaglutide reaches the stomach, SNAC creates a microenvironment of elevated local pH around the tablet, temporarily protecting semaglutide from acid hydrolysis. More importantly, SNAC acts as a transient permeability enhancer at the gastric mucosa specifically — facilitating transcellular transport of semaglutide across gastric epithelial cells via a transcytosis mechanism. This gastric absorption bypasses much of the small intestinal enzymatic exposure (PMC7499355).

The result: oral semaglutide achieves approximately 1% absolute bioavailability — an extremely low number in absolute terms, but sufficient for clinical effect because semaglutide is highly potent at low concentrations. The clinical dosing (3 mg, 7 mg, or 14 mg orally vs. 0.25–2 mg subcutaneously) reflects this ~10-fold dose escalation needed to achieve comparable plasma levels.

SNAC technology is specific to semaglutide’s development and does not generalize to other peptides without reformulation. Its significance for research is that it demonstrates oral peptide delivery is achievable — but that it requires specialized formulation science for each molecule.

Nasal Delivery: Semax and Selank

The nasal route occupies a unique position in peptide delivery. The nasal mucosa is richly vascularized with a thin epithelial barrier, and it lacks the enzymatic gauntlet of the GI tract. These properties make nasal delivery viable for certain peptides that are too small and stable enough to survive mucosal absorption.

Two research peptides — Semax and Selank — were specifically developed by the Institute of Molecular Genetics of the Russian Academy of Sciences with intranasal delivery as the primary administration route.

Semax

Semax is a synthetic heptapeptide (MEHFPGP) derived from the adrenocorticotropic hormone (ACTH) 4–10 fragment. At 7 amino acids and approximately 865 Da, it is small enough to be absorbed across nasal mucosa at meaningful rates. Russian clinical literature has investigated intranasal Semax in neuroprotection and cognitive research contexts, with the intranasal route used in both clinical and preclinical settings. Its small size and structural stability relative to larger peptides contribute to its suitability for nasal delivery (PMC6149565).

Selank

Selank is a synthetic heptapeptide (TKPRPGP) derived from the immunomodulatory peptide tuftsin (TKPR) with a Pro-Gly-Pro stabilizing sequence appended at the C-terminus. The Pro-Gly-Pro addition was specifically engineered to improve nasal mucosal stability and extend the peptide’s half-life at the site of administration. Selank has been investigated in anxiolytic and nootropic research, with intranasal administration used in the published literature (PMC7309620).

Limitations of Nasal Delivery

Nasal delivery works for small, stable peptides. For larger peptides (above approximately 1,500–2,000 Da), nasal bioavailability drops significantly due to the limitations of passive diffusion and the increasing difficulty of transcytosis for larger molecules. Larger peptides also face enzymatic degradation from nasal mucosa proteases, though this environment is considerably less aggressive than the GI tract. Mucociliary clearance — the nose’s natural mucus transport mechanism — also limits how long a peptide remains in contact with the absorptive epithelium.

Transdermal and Other Emerging Routes

Transdermal delivery — application to the skin surface for absorption into underlying capillaries — is routinely viable for small lipophilic molecules but faces major challenges with peptides. The stratum corneum (the outermost skin layer) is an effective barrier to large, hydrophilic molecules like most peptides. Conventional transdermal patches do not work for peptide delivery.

Research into transdermal peptide delivery has explored several approaches to overcome the stratum corneum barrier:

• Chemical permeation enhancers — Fatty acids, surfactants, and other molecules that transiently disrupt stratum corneum lipid organization. Limited efficacy for peptides above ~1,000 Da.
• Microneedle arrays — Tiny needles (typically 150–900 μm long) that penetrate the stratum corneum without reaching pain receptors, creating channels for drug delivery. Active research area for insulin and GLP-1 peptides in preclinical models.
• Iontophoresis — Application of a small electrical current to drive charged molecules across the skin. Has shown some efficacy for small peptides in research settings.
• Ultrasound-mediated delivery (sonophoresis) — Low-frequency ultrasound transiently disrupts skin barrier structure, enhancing permeability. Investigated primarily in academic research settings.

None of these approaches has produced a commercially viable transdermal peptide product for large peptides as of 2026, though the microneedle approach is the most actively studied for future applications (PMC9918083).

Route Comparison Table

Route	Typical Bioavailability	Suitable Peptide Size	Key Barrier	Example Peptides
Subcutaneous injection	75–95%	Any	None significant	Retatrutide, BPC-157, TB-500, CJC-1295
Intravenous injection	100%	Any	Rapid clearance	Research protocols requiring fast Cmax
Intramuscular injection	75–90%	Any	None significant	Many short-acting peptides
Oral (standard)	<1% (usually ~0%)	Very small only	GI enzymes, mucosal barrier, first-pass	BPC-157 (acid-stable), cyclic peptides
Oral (SNAC-enhanced)	~1% absolute	Formulation-specific	Requires molecular co-formulation	Oral semaglutide (Rybelsus)
Intranasal	5–30% (peptide-dependent)	<1,500 Da preferred	Mucociliary clearance, mucosal proteases	Semax, Selank, oxytocin
Transdermal	<5% (most peptides ~0%)	<500 Da, lipophilic	Stratum corneum	Investigational / microneedle research

Future Directions in Peptide Delivery

The field is actively developing approaches to overcome oral and non-injectable delivery limitations. The most promising areas for large peptide delivery include:

• Oral peptide delivery vehicles — Nanoparticle-based systems (liposomes, polymeric nanoparticles, solid lipid nanoparticles) that encapsulate peptides and protect them from GI degradation while facilitating epithelial transport. Multiple GLP-1 and insulin analogs are in preclinical development using nanocarrier systems.
• Oral absorption enhancers beyond SNAC — Alternative chemical enhancers (acyl carnitines, bile salt analogs) that could be paired with different peptide structures.
• Microneedle patch platforms — Dissolving microneedle arrays loaded with peptide cargo, allowing skin delivery without conventional injection. Closest to clinical application for insulin analogs.
• Cyclic and stapled peptides — Structural modifications (cyclization, hydrocarbon stapling) that confer protease resistance and enhanced membrane permeability, potentially improving oral and mucosal bioavailability for specific peptide sequences.

None of these approaches has replaced injectable delivery for research-grade peptides as of 2026, but the trajectory of the field suggests that delivery options will continue to expand. SNAC technology and oral semaglutide represent proof-of-concept that the problem is not unsolvable — only molecule-specific and formulation-intensive (PMC9918083).

Implications for Research Protocol Design

For researchers designing protocols involving peptides, the delivery route is not just a logistical choice — it determines what bioavailability assumption the protocol should use, how to calculate doses, and what plasma concentration profiles to expect. Key practical considerations:

• Always use the route validated in the published literature for the specific peptide. Switching from SC to oral without formulation science backing will produce dramatically different (usually much lower) plasma levels.
• BPC-157 is one of the rare exceptions where oral administration has been used in published animal research, but this is due to the peptide’s specific acid stability — not a principle that generalizes.
• Nasal administration for Semax and Selank follows the published research literature. Both were developed as intranasal peptides, and the published data uses this route.
• Reconstituted peptides for injection should be prepared with bacteriostatic water and stored at 2–8°C after reconstitution. Repeated freeze-thaw cycles degrade most peptides and should be avoided.

Key Research References

Study / Source	Year	Type	Focus	Reference
Brayden et al.	2020	Review	SNAC mechanism in oral semaglutide delivery	PMC7499355
BPC-157 Multifunctionality Review	2025	Literature review	BPC-157 gastric acid stability and oral research	PMC11859134
Semax pharmacology review	2018	Review	Intranasal Semax neuroprotection research	PMC6149565
Selank anxiolytic review	2020	Review	Intranasal Selank and BDNF modulation	PMC7309620
Microneedle peptide delivery review	2023	Review	Transdermal microneedle delivery for peptides	PMC9918083
Retatrutide pharmacokinetics	2025	Review	Albumin binding and SC depot mechanism	PMC12026077